Literature DB >> 12921223

Plasma nitrate levels in deficit versus non-deficit forms of schizophrenia.

Eiji Suzuki1, Toshio Nakaki, Makoto Nakamura, Hitoshi Miyaoka.   

Abstract

OBJECTIVE: To determine whether nitric oxide production levels differ in patients with deficit and non-deficit forms of schizophrenia.
METHODS: We investigated plasma nitrate levels, an index of in vivo nitric oxide production, in patients with deficit syndrome (n = 11) and non-deficit syndrome (n = 14) and healthy controls (n = 12) with a combination of high-performance liquid chromatography and the Griess reaction.
RESULTS: There was no difference found in mean plasma nitrite levels, but plasma nitrate levels of patients with deficit syndrome were significantly lower than those with non-deficit syndrome (28.0 [SEM 2.5] micromol/L v. 44.2 [SEM 5.5] micromol/L, p < 0.05).
CONCLUSIONS: A decline in nitric oxide production may be involved in primary negative symptoms in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12921223      PMCID: PMC165793     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  45 in total

1.  Antipsychotic, antidepressant, anxiolytic, and anticonvulsant drugs induce type II nitric oxide synthase mRNA in rat brain.

Authors:  Eiji Suzuki; Toshio Nakaki; Futoshi Shintani; Shigenobu Kanba; Hitoshi Miyaoka
Journal:  Neurosci Lett       Date:  2002-11-29       Impact factor: 3.046

Review 2.  Molecular pathology of schizophrenia: more than one disease process?

Authors:  T J Crow
Journal:  Br Med J       Date:  1980-01-12

3.  Deficit and nondeficit forms of schizophrenia: the concept.

Authors:  W T Carpenter; D W Heinrichs; A M Wagman
Journal:  Am J Psychiatry       Date:  1988-05       Impact factor: 18.112

4.  The Schedule for the Deficit syndrome: an instrument for research in schizophrenia.

Authors:  B Kirkpatrick; R W Buchanan; P D McKenney; L D Alphs; W T Carpenter
Journal:  Psychiatry Res       Date:  1989-11       Impact factor: 3.222

5.  NMDA receptor activation induces nitric oxide synthesis from arginine in rat brain slices.

Authors:  J Garthwaite; G Garthwaite; R M Palmer; S Moncada
Journal:  Eur J Pharmacol       Date:  1989-10-17       Impact factor: 4.432

6.  The diagnosis and understanding of schizophrenia. Part III. Speculations on the processes that underlie schizophrenic symptoms and signs.

Authors:  J S Strauss; W T Carpenter; J J Bartko
Journal:  Schizophr Bull       Date:  1974       Impact factor: 9.306

7.  Allelic association of the neuronal nitric oxide synthase (NOS1) gene with schizophrenia.

Authors:  T Shinkai; O Ohmori; H Hori; J Nakamura
Journal:  Mol Psychiatry       Date:  2002       Impact factor: 15.992

8.  Lateral ventricular size in schizophrenia: relationship to the disease process and its clinical manifestations.

Authors:  D G Owens; E C Johnstone; T J Crow; C D Frith; J R Jagoe; L Kreel
Journal:  Psychol Med       Date:  1985-02       Impact factor: 7.723

9.  The disabilities of chronic schizophrenia--their nature and the factors contributing to their development.

Authors:  D G Cunningham Owens; E C Johnstone
Journal:  Br J Psychiatry       Date:  1980-04       Impact factor: 9.319

10.  Kraepelinian schizophrenia: a subgroup of schizophrenia?

Authors:  R S Keefe; R C Mohs; M Davidson; M F Losonczy; J M Silverman; J C Lesser; T B Horvath; K L Davis
Journal:  Psychopharmacol Bull       Date:  1988
View more
  9 in total

1.  Imbalanced free radicals and antioxidant defense systems in schizophrenia: a comparative study.

Authors:  Hui-chun Li; Qiao-zhen Chen; Ying Ma; Jun-fu Zhou
Journal:  J Zhejiang Univ Sci B       Date:  2006-12       Impact factor: 3.066

Review 2.  Oxidative stress in schizophrenia: an integrated approach.

Authors:  Byron K Y Bitanihirwe; Tsung-Ung W Woo
Journal:  Neurosci Biobehav Rev       Date:  2010-10-23       Impact factor: 8.989

3.  Sodium nitroprusside is effective in preventing and/or reversing the development of schizophrenia-related behaviors in an animal model: The SHR strain.

Authors:  Mariana C Diana; Fernanda F Peres; Veronica Justi; Rodrigo A Bressan; Acioly L T Lacerda; José Alexandre Crippa; Jaime E C Hallak; Vanesssa Costhek Abilio
Journal:  CNS Neurosci Ther       Date:  2018-04-14       Impact factor: 5.243

Review 4.  Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view.

Authors:  Jeffrey K Yao; Matcheri S Keshavan
Journal:  Antioxid Redox Signal       Date:  2011-04-21       Impact factor: 8.401

5.  Interaction of apelin, elabela and nitric oxide in schizophrenia patients.

Authors:  Zekiye Catak; Hilal Kaya; Esra Kocdemir; Kader Ugur; Guzel Saadet Pilten; Meltem Yardim; Ibrahim Sahin; Agirbas Esra Piril; Suleyman Aydin
Journal:  J Med Biochem       Date:  2020-01-23       Impact factor: 3.402

6.  Meta-analysis of oxidative stress in schizophrenia.

Authors:  Joshua Flatow; Peter Buckley; Brian J Miller
Journal:  Biol Psychiatry       Date:  2013-05-15       Impact factor: 13.382

7.  Status of plasma nitric oxide and non-enzymatic antioxidants before and after antipsychotic treatment in Nigerian patients with schizophrenia.

Authors:  Og Arinola; Ob Idonije
Journal:  J Res Med Sci       Date:  2009-01       Impact factor: 1.852

Review 8.  Multidimensional Connectomics and Treatment-Resistant Schizophrenia: Linking Phenotypic Circuits to Targeted Therapeutics.

Authors:  Mary-Anne B MacKay; John W Paylor; James T F Wong; Ian R Winship; Glen B Baker; Serdar M Dursun
Journal:  Front Psychiatry       Date:  2018-10-30       Impact factor: 4.157

Review 9.  The Nitric Oxide (NO) Donor Sodium Nitroprusside (SNP) and Its Potential for the Schizophrenia Therapy: Lights and Shadows.

Authors:  Elli Zoupa; Nikolaos Pitsikas
Journal:  Molecules       Date:  2021-05-26       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.